| Santen Pharmaceutical Co., Ltd. | |
| Native Name: | 参天製薬株式会社 |
| Type: | Public KK |
| Traded As: | OSE 4536 |
| Founder: | Kenkichi Taguchi |
| Foundation: | Osaka, Japan |
| Location: | Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka 530-8552, Japan |
| Key People: | Akira Kurokawa, (CEO and President) |
| Industry: | Pharmaceutical |
| Revenue: | $ 2.429 billion (FY 2018) (¥ 243.0 billion) (FY 2018) |
| Net Income: | $ 175.661 million (FY 2012) (¥ 16.521 billion) (FY 2012) |
| Num Employees: | 3,805(consolidated) (as of March 31, 2018) |
| Footnotes: | [1] [2] |
, is a Japanese pharmaceutical company, specializing in ophthalmology. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.[3]
The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.[4] In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products.[5]
Santen has 3 plants located in Hōdatsushimizu, Ishikawa, in Tampere and in Suzhou, 21 subsidiary companies located in Japan, the US, the Netherlands, Finland, United Kingdom & Ireland, Spain, Switzerland, Italy, France,[6] Germany, Sweden, China, South Korea, Taiwan, India, Thailand, Malaysia, the Philippines and Singapore. Its R&D center is located in Ikoma, Nara.[7] [8]